Ahn SM, Oh JS, Hong S, et al. - The present study was conducted to correlate the prophylactic effect between regular-dose (RD, 1.2 mg/day) and low-dose (LD, 0.6 mg/day) colchicine on gout flare when initiating urate-lowering therapy. Researchers performed a retrospective cohort study including gout patients who were initiated on allopurinol or febuxostat and colchicine therapy and followed them up for 3 months. The rates of gout flare and adverse events were analyzed according to the dose of colchicine. The inverse probability of treatment weighting and weighted logistic regression analysis was conducted to evaluate the treatment effect. They conducted an analysis of gout flares and adverse events on an intention-to-treat and per-protocol basis. In this study, 177 (42.2%) patients received LD colchicine, whereas 242 (57.8%) patients received RD colchicine out of the total 419 patients with gout. The outcomes imply that in comparison with RD colchicine, LD colchicine can adequately prevent gout flare with fewer adverse events. Events of gout flare were not significantly different between the LD and RD groups in IPTW-adjusted analysis. However, LD colchicine was associated with a lower rate of adverse events than RD colchicine.